JP2011115169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011115169A5 JP2011115169A5 JP2011005342A JP2011005342A JP2011115169A5 JP 2011115169 A5 JP2011115169 A5 JP 2011115169A5 JP 2011005342 A JP2011005342 A JP 2011005342A JP 2011005342 A JP2011005342 A JP 2011005342A JP 2011115169 A5 JP2011115169 A5 JP 2011115169A5
- Authority
- JP
- Japan
- Prior art keywords
- kcnb
- seq
- tag
- amino acid
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101001049835 Homo sapiens Potassium channel subfamily K member 3 Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102100023207 Potassium channel subfamily K member 3 Human genes 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18691500P | 2000-03-03 | 2000-03-03 | |
| US60/186,915 | 2000-03-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001565895A Division JP2004500825A (ja) | 2000-03-03 | 2001-03-02 | Ｋｃｎｂ：新規なカリウムチャネルタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011115169A JP2011115169A (ja) | 2011-06-16 |
| JP2011115169A5 true JP2011115169A5 (enExample) | 2012-03-01 |
Family
ID=22686808
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001565895A Pending JP2004500825A (ja) | 2000-03-03 | 2001-03-02 | Ｋｃｎｂ：新規なカリウムチャネルタンパク質 |
| JP2011005342A Pending JP2011115169A (ja) | 2000-03-03 | 2011-01-13 | Ｋｃｎｂ：新規なカリウムチャネルタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001565895A Pending JP2004500825A (ja) | 2000-03-03 | 2001-03-02 | Ｋｃｎｂ：新規なカリウムチャネルタンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7462465B2 (enExample) |
| EP (1) | EP1266003B1 (enExample) |
| JP (2) | JP2004500825A (enExample) |
| CN (1) | CN1426468A (enExample) |
| AT (1) | ATE538201T1 (enExample) |
| AU (2) | AU2001250794B2 (enExample) |
| CA (1) | CA2401906C (enExample) |
| ES (1) | ES2378417T3 (enExample) |
| IL (2) | IL151564A0 (enExample) |
| NZ (1) | NZ521205A (enExample) |
| WO (1) | WO2001066741A2 (enExample) |
| ZA (1) | ZA200206999B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057846A2 (en) * | 2001-12-31 | 2003-07-17 | Algos Therapeutics, Inc. | Methods and materials for modulating task-3 |
| WO2005052586A2 (en) * | 2003-11-27 | 2005-06-09 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 3 (kcnk3) |
| WO2005075510A1 (en) * | 2004-02-04 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 9 (kcnk9) |
| US12416024B2 (en) | 2018-03-29 | 2025-09-16 | Transworld Technologies Inc. | Biologically enhanced oil recovery methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2744730B1 (fr) | 1996-02-08 | 1998-04-17 | Centre Nat Rech Scient | Nouvelle famille de canaux potassium de mammifere, leur clonage et leur utilisation notamment pour le criblage de drogues |
| EP1051485A1 (en) | 1998-01-27 | 2000-11-15 | Smithkline Beecham Plc | Trek-1 like two pore potassium channel |
| EP1090118A2 (en) * | 1998-06-26 | 2001-04-11 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
| DE69938667D1 (de) | 1998-11-09 | 2008-06-19 | Centre Nat Rech Scient | Neue familie von säugetier-kaliumkanälen, ihre klonierung und ihre verwendung, besonders für das drogenscreening |
| WO2000053628A2 (en) * | 1999-03-05 | 2000-09-14 | Smithkline Beecham Plc | Genes encoding human potassium channel proteins |
| US20020137202A1 (en) * | 1999-12-21 | 2002-09-26 | Catherine Burgess | Novel proteins and nucleic acids encoding same |
| GB2373500B (en) | 2000-02-04 | 2004-12-15 | Aeomica Inc | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| EP1381626A2 (en) | 2000-04-06 | 2004-01-21 | Incyte Genomics, Inc. | Human transporters and ion channels |
| AU2001294724A1 (en) | 2000-09-25 | 2002-04-08 | Millennium Pharmaceuticals, Inc. | 56115, a novel human twik potassium channel and uses therefor |
-
2001
- 2001-03-02 CN CN01808748A patent/CN1426468A/zh active Pending
- 2001-03-02 AU AU2001250794A patent/AU2001250794B2/en not_active Ceased
- 2001-03-02 AT AT01924111T patent/ATE538201T1/de active
- 2001-03-02 NZ NZ521205A patent/NZ521205A/en unknown
- 2001-03-02 JP JP2001565895A patent/JP2004500825A/ja active Pending
- 2001-03-02 WO PCT/US2001/006801 patent/WO2001066741A2/en not_active Ceased
- 2001-03-02 US US09/798,584 patent/US7462465B2/en not_active Expired - Fee Related
- 2001-03-02 ES ES01924111T patent/ES2378417T3/es not_active Expired - Lifetime
- 2001-03-02 IL IL15156401A patent/IL151564A0/xx unknown
- 2001-03-02 EP EP01924111A patent/EP1266003B1/en not_active Expired - Lifetime
- 2001-03-02 CA CA2401906A patent/CA2401906C/en not_active Expired - Lifetime
- 2001-03-02 AU AU5079401A patent/AU5079401A/xx active Pending
-
2002
- 2002-08-30 ZA ZA200206999A patent/ZA200206999B/en unknown
- 2002-09-02 IL IL151564A patent/IL151564A/en not_active IP Right Cessation
-
2008
- 2008-01-03 US US11/968,795 patent/US20080234470A1/en not_active Abandoned
-
2011
- 2011-01-13 JP JP2011005342A patent/JP2011115169A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI638829B (zh) | 分枝桿菌抗原疫苗 | |
| Oudshoorn et al. | HERC6 is the main E3 ligase for global ISG15 conjugation in mouse cells | |
| JP2007508846A5 (enExample) | ||
| JP2017518037A5 (enExample) | ||
| PH12022550230A1 (en) | Antigen binding proteins specifically binding mage-a | |
| IL309801B2 (en) | Using nucleosome interacting protein domains to enhance targeted genome modification | |
| JP2019526248A5 (enExample) | ||
| JP2011115169A5 (enExample) | ||
| Spencer et al. | The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B. 1.351) and other variants of concern in preclinical studies | |
| JP2014509851A5 (enExample) | ||
| KR20160130216A (ko) | 헤테로올리고머 미코박테리아 항원의 융합물 | |
| JP2008543314A5 (enExample) | ||
| JP2018500009A5 (enExample) | ||
| WO2006137836A3 (en) | Bacterial vector systems | |
| JP2014198050A5 (enExample) | ||
| FI3448879T3 (fi) | Claudin-6 -peptidejä | |
| ES2827020T3 (es) | Respuestas inmunitarias antitumorales contra autoepítopos modificados | |
| HRP20240359T1 (hr) | Peptidi iz piwil1 | |
| JP2004500825A5 (enExample) | ||
| JPWO2020181102A5 (enExample) | ||
| JP6864364B2 (ja) | 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、ｄｎａ、及びベクター | |
| JP2007529199A5 (enExample) | ||
| Maity et al. | Intrinsically Disordered Ku Protein-Derived Cell-Penetrating Peptides | |
| CN103230599B (zh) | 一种增强多肽药物从细胞内体逃离的蛋白载药系统及其应用 | |
| EP2625196B1 (en) | Fusion polypeptides comprising tir and dimerization domain for modulation of tlr/innate immunity signaling |